Policy / Pricing SCOTUS backs generic firm Hikma in skinny label dispute PharmaphorumSCOTUS has delivered its ruling in a closely watched 'skinny label' lawsuit between Amarin and Hikma, which could have far-reaching implications.Read full story pharminent June 4, 2026 (Last updated: June 5, 2026) Pharmaphorum SCOTUS has delivered its ruling in a closely watched ‘skinny label’ lawsuit between Amarin and Hikma, which could have far-reaching implications. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: ADC Therapeutics slumps on cancer drug safety scareNext: Boan Biotech Submits BLA to FDA for Two Denosumab Biosimilars Related Stories Policy / Pricing US generic tariff reprieve on the rocks as Trump proposes 100% rate in 2028 pharminent July 22, 2026 Policy / Pricing UK commits to pharma IP protection in Swiss trade deal pharminent July 16, 2026 Policy / Pricing Germany approves healthcare costs overhaul despite significant pharma opposition pharminent July 13, 2026
